DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

Not Applicable

Withdrawn

Conditions: ER-positive Her2-negative Early Breast Cancer

Interventions: Diagnostic Test: Genomic test

First Posted Date: 2017-03-15

Last Posted Date: 2017-08-28

Lead Sponsor: UNICANCER

Registration Number: NCT03080428

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Phase 3

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib 125mg
Drug: Fulvestrant Injectable Product
Drug: Aromatase Inhibitors

First Posted Date: 2017-03-14

Last Posted Date: 2024-11-12

Lead Sponsor: UNICANCER

Target Recruit Count: 1017

Registration Number: NCT03079011

Locations: 🇫🇷
Clinique PASTEUR-CFRO, Brest, France
🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷
Clinique de l'Europe, Amiens, France

and more 79 locations

Tracking Triple-negative Breast Cancer Evolution Through Therapy

Not Applicable

Active, not recruiting

Conditions: Triple-Negative Breast Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biopsy (optional)
Procedure: Biopsy (metastatic)

First Posted Date: 2017-03-13

Last Posted Date: 2025-02-20

Lead Sponsor: UNICANCER

Target Recruit Count: 149

Registration Number: NCT03077776

Locations: 🇫🇷
Centre Leon Bérard, Lyon, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre George François Leclerc, Dijon, France

and more 7 locations

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Phase 2

Completed

Conditions: Cancer With POLE Exonucleasic Domain Mutation
Skin Neoplasms
Carcinoma, Renal Cell
Head and Neck Neoplasm
Microsatellite Instability
Penile Neoplasms

Interventions: Drug: Nivolumab

First Posted Date: 2017-01-06

Last Posted Date: 2024-02-28

Lead Sponsor: UNICANCER

Target Recruit Count: 269

Registration Number: NCT03012581

Locations: 🇫🇷
Gustave Roussy Cancer Campus, Villejuif, France

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Phase 2

Completed

Conditions: Sarcoma
Neoplasms, Germ Cell and Embryonal
Central Nervous System Neoplasm
Carcinoma, Neuroendocrine
Ovarian Neoplasm
Thyroid Neoplasm
NK/T-cell Lymphoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-01-06

Last Posted Date: 2024-02-28

Lead Sponsor: UNICANCER

Target Recruit Count: 334

Registration Number: NCT03012620

Locations: 🇫🇷
Gustave Roussy Cancer Campus, Villejuif, France

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Nivolumab

First Posted Date: 2017-01-06

Last Posted Date: 2021-10-06

Lead Sponsor: UNICANCER

Target Recruit Count: 730

Registration Number: NCT03013335

Locations: 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷
Centre Georges-Francois Leclerc, Dijon, France
🇫🇷
Institut Paoli-Calmettes, Marseille, France

and more 4 locations

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Phase 2

Completed

Conditions: Menopause
Hormone Antagonist
Breast Cancer
Estrogen Receptor Positive Tumor

Interventions: Drug: Immune-attractant
Drug: Durvalumab
Procedure: Biopsy

First Posted Date: 2016-12-20

Last Posted Date: 2020-09-30

Lead Sponsor: UNICANCER

Target Recruit Count: 61

Registration Number: NCT02997995

Locations: 🇪🇸
HU Arnau de Vilanova, Lleida, Spain
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Institut Jean Godinot, Reims, France

and more 26 locations

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
Drug: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil

First Posted Date: 2016-12-02

Last Posted Date: 2025-02-20

Lead Sponsor: UNICANCER

Target Recruit Count: 219

Registration Number: NCT02980510

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
Chu Saint Eloi, Montpellier, France
🇫🇷
Centre Léon Berard, Lyon, France

and more 3 locations

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Phase 3

Active, not recruiting

Conditions: Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

Interventions: Drug: Irinotecan
Drug: Folfox Protocol

First Posted Date: 2016-11-18

Last Posted Date: 2024-09-30

Lead Sponsor: UNICANCER

Target Recruit Count: 792

Registration Number: NCT02967289

Locations: 🇫🇷
Hôpital Saint Antoine, Paris, France
🇨🇦
The PEI Cancer Treatment Centre Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada
🇨🇦
Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada

and more 14 locations

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss

Phase 1

Terminated

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: Copanlisib
Drug: Cetuximab

First Posted Date: 2016-07-04

Last Posted Date: 2021-03-29

Lead Sponsor: UNICANCER

Target Recruit Count: 11

Registration Number: NCT02822482

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest, Angers, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Centre Georges François Leclerc, Dijon, France

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy